Vitae’s Debt Financing Braves Renin Inhibitor Risk, FDA Wariness In Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Two lenders wade in despite harsh credit environment for biotechs.
You may also be interested in...
Second Collaboration With Boehringer Provides Extended Cash Runway For Vitae
Previously partnered on a diabetes program, the two companies now will collaborate on a BACE inhibitor will potential as a disease-altering therapy in Alzheimer’s.
Second Collaboration With Boehringer Provides Extended Cash Runway For Vitae
Previously partnered on a diabetes program, the two companies now will collaborate on a BACE inhibitor will potential as a disease-altering therapy in Alzheimer’s.
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.